IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
IRADIMED CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$87.65−0.62 (-0.70%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 49.0
- Dividend yield
- –
IRADIMED CORP revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total devices revenue | $13.85M | $15.39M | – | – | $14.61M | $12.96M | – | – | – | – | – | – | 67.7% | -5.2% |
| MRI Compatible Patient Vital Signs Monitoring Systems | $6.67M | $7.11M | – | – | $5.94M | $6.55M | – | – | – | – | – | – | 32.6% | +12.1% |
| "MRI Compatible Intravenous (""IV"") Infusion Pump Systems" | $6.43M | $7.66M | – | – | $8.19M | $6.00M | – | – | – | – | – | – | 31.4% | -21.5% |
| Disposables | $4.79M | $4.89M | – | – | $4.20M | $4.95M | – | – | – | – | – | – | 23.4% | +14.0% |
| Services and other | $1.07M | $1.04M | – | – | $999.00K | $1.04M | – | – | – | – | – | – | 5.2% | +6.7% |
| Amortization of extended maintenance agreements | $758.00K | $659.00K | – | – | $592.00K | $560.00K | – | – | – | – | – | – | 3.7% | +28.0% |
| Ferro Magnetic Detection Systems | $756.00K | $621.00K | – | – | $482.00K | $418.00K | – | – | – | – | – | – | 3.7% | +56.8% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $16.72M | $18.03M | $18.30M | $18.11M | $18.19M | $15.95M | $16.51M | $15.21M | $15.49M | $13.41M | $13.65M | $13.95M | 81.7% | -8.1% |
| International | $3.75M | $3.95M | $4.39M | $3.09M | $2.22M | $3.56M | $2.88M | $3.12M | – | – | – | – | 18.3% | +68.8% |
| International | – | – | – | – | $2.22M | $3.56M | $2.88M | $3.12M | $2.44M | $4.19M | $3.80M | $2.56M | – | – |
From the segment and revenue-disaggregation notes of Iradimed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.